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Abstract
Although metastatic disease is responsible for the majority of cancer deaths, tests of novel immunotherapies in mouse 
tumour models often focus on primary tumours without determining whether these therapies also target metastatic disease. 
This study examined the impact of depleting  Foxp3+ regulatory T cells (Treg), on lung metastases, using a mouse model 
of breast cancer. After Treg-depletion, generation of an immune response to the primary tumour was a critical determinant 
for limiting development of metastasis. Indeed, resection of the primary tumour abrogated any effect of Treg-depletion on 
metastases. In addition, whilst the immune response, generated by the primary tumour, prevented metastases development, 
it had little impact on controlling established disease. Collectively, the data indicate that metastatic cells in the lung are not 
controlled by immune responses induced by the primary tumour. These findings indicate that targeting Tregs alone will not 
suffice for treating lung metastases.
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Introduction
Metastasis is the primary cause of morbidity and mortality 
for individuals with cancer, accounting for around 90% of 
patient deaths [1–3]. In order for metastasis to occur, dis-
seminated tumour cells must survive migration through 
the vascular or lymphatic system where they may become 
susceptible to immune attack, and extravasate into the new 
tissue, re-establishing tumours within a metastatic niche 
(reviewed in [2]). Given the bottlenecks involved, the 
process is inefficient, with only a few highly selected cells 
surviving the process. The immune system most likely rep-
resents a significant impediment to metastases since outside 
of the primary tumour site, circulating tumour cells may 
become vulnerable to immune attack; however, tumour-
induced, systemic immunomodulation may aid their survival 
and dissemination to potential sites of metastases (reviewed 
in [4, 5]). Once a metastatic niche is established, locally act-
ing immunosuppressive mechanisms may serve to promote 
growth of secondary lesions [6, 7].
CD4+Foxp3+ T cells (Treg) represent a potent arm of 
tumour-induced immunosuppression [8]. They are signifi-
cantly enriched in many mouse and human tumours, and 
several studies have provided evidence that depletion of 
Treg promotes immune-mediated rejection at least of pri-
mary tumours ([9, 10] and reviewed in [8]). Few studies 
have examined the impact of Treg-depletion on spontane-
ous metastatic disease. This is a critical aspect of cancer 
immunotherapy as metastatic disease is the main cause of 
cancer-related death. In addition, it is known that Treg are 
often found at high frequencies in the circulation of cancer 
patients supporting the hypothesis that their presence aids 
survival of disseminated tumour cells (reviewed in [11]). 
To address this, we have used the 4T1 mouse breast cancer 
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model. Following inoculation of 4T1 cells and subsequent 
growth in the mammary fat pad, these tumours sponta-
neously metastasise first to the lung, followed by liver, 
brain and bone. The tumour is poorly immunogenic and 
triple negative for common breast cancer markers [12–14]. 
With these characteristics in mind, 4T1 tumours have been 
widely used as a clinically relevant model for studying 
different stages of breast cancer progression and for test-
ing drugs designed to impede malignancy (reviewed in 
[15]). Furthermore, as primary 4T1 tumours can easily 
be surgically excised, mimicking the treatment of human 
breast cancer [12–14], the impact of therapy on meta-
static disease can be assessed in the presence or absence 
of the primary tumour. Specifically, we used this model to 
address the impact of Treg on breast cancer metastasis. We 
tested whether any effect of Treg-depletion on metastatic 
disease was linked to primary tumour size and/or the abil-
ity to mount an efficient immune response to the primary 
tumour. In addition, we examined whether there was any 




DEpletion of REGulatory T cell (DEREG) mice, devel-
oped by Professor Tim Sparwasser, are a strain of BALB/C 
mice developed using a bacterial artificial chromosome 
(BAC) containing the foxp3 locus and a diphtheria toxin 
receptor (DTR)-eGFP fusion protein inserted into the first 
exon of the foxp3 gene [16]. As described previously, the 
Treg of DEREG mice can be selectively ablated by injec-
tion of diphtheria toxin (DTx). DEREG mice and litter-
mates were bred and housed in filter-top cages in specific 
pathogen-free condition. Experiments were performed in 
accordance with Home Office UK guidelines.
Analysis of Treg by flow cytometry
Single-cell suspensions prepared from tumours, spleens 
and LNs were subjected to red blood cell lysis buffer and 
subsequently stained using a fixable dead cell staining kit 
(LIVE/DEAD Aqua, Invitrogen). Cells were then surface 
stained with CD4-specific antibodies (Biolegend) before 
fixation/permeabilisation (eBioscience) and staining with 
Foxp3-specific antibodies (eBioscience). Fixed cells were 
run through a Novocyte (ACEA) flow cytometer and ana-
lysed using FlowJo software.
Culture and injection of 4T1 cells
4T1 (obtained from ATCC (CRL-2539)), is a murine mam-
mary carcinoma that closely mimics stage 4 triple-negative 
human breast cancer. The cells were maintained in complete 
RPMI medium supplemented with 10% Foetal Calf Serum 
(FCS) 2 mM L-glutamine, 1 mM sodium pyruvate, 50 μg/
ml penicillin and streptomycin at 37 °C, 5%  CO2. Cells 
were split up to 3 times a week and grown for 3–6 passages 
before being injected into the mammary fat pads of DEREG 
mice. Tumours were measured up to 3 times per week from 
day 7 until the tumour was resected or until the mouse was 
killed. Two perpendicular measurements were taken of the 
tumour from which the volume was calculated. Tumour 
volume = (length × width × short)*(3.14/6), [where short 
equals the lower of the length and width measurements and 
provides an estimate of height] [10]. In some experiments 
4T1 cells were injected intravenously into the tail vein.
Surgical removal of primary tumour
Tumours were measured before induction of anaesthesia 
(isofluorane) and subcutaneous injection with the anti-
inflammatory analgesic, Metacam (Boehringer Ingelheim). 
The tumour and the surrounding area were shaved and 
swabbed with Hibiscrub antibacterial wash and surgical 
spirit. Aseptic techniques were used to excise the tumour and 
close the wound using horizontal mattress sutures (Ethicon). 
Mice, placed in a heated recovery chamber until conscious-
ness was regained, were monitored postoperative for well-
being and suture strength.
Cancer vaccination
For primary tumour control studies prior to tumour inocu-
lation 1 × 107 plaque-forming units (pfu) of vaccinia virus 
expressing the 4T1 immunodominant peptide epitope, 
SPSYVYHQF, named AH1 (Vac-AH1) or vaccinia express-
ing influenza nucleoprotein (Vac-NP) as an irrelevant con-
trol, were administered i.p [9, 17, 18]. Fourteen days post-
vaccination the antigen-specific response was boosted by 
a second vaccination with either 1 × 107 pfu of Vac-AH1 
or Vac-NP. 4T1 tumours were inoculated 7 days later. For 
studies relating to metastatic control, following resection of 
primary tumours, mice were administered DTx or PBS as 
indicated every other day from day 1 postsurgery. Mice were 
vaccinated at day 2 postresection with either 1 × 107 pfu of 
Vac-AH1 or Vac-NP. To determine vaccination efficacy, 
splenocytes were stained 14 days postvaccination using a 
dead cell staining kit (LIVE/DEAD Aqua, Invitrogen). Cells 
were stained with a H-2Ld PE-labelled dextramer comprising 
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peptide SPSYVYHQF (Immudex) and subsequently surface 
stained with CD3-, CD4- and CD8-specific antibodies. Cells 
were run through a Novocyte (ACEA) flow cytometer and 
analysed using FlowJo software.
Analysis of  CD8+ IFN‑γ production by flow cytometry
Intracellular IFN-γ staining of CD8 T cells was performed 
using single-cell suspensions derived from lungs. Cultures 
were stimulated at 37 °C in complete RPMI with phorbol12-
myristate 13-acetate (PMA, Sigma-Aldrich) (20 nM) and 
ionomycin (1 μg/ml) (Sigma-Aldrich) for 5 h; brefeldin 
(1 μg/ml, Biolegend) was added for the last 4 h. After incu-
bation cells were stained using a fixable dead cell staining 
kit (LIVE/DEAD Aqua, Invitrogen). Cells were then surface 
stained with CD8-specific antibodies (Biolegend) before fix-
ation/permeabilisation (BD Biosciences) and staining with 
IFN-γ-specific antibodies (Biolegend). Fixed cells were run 
through a Novocyte (ACEA) flow cytometer and analysed 
using FlowJo software.
Clonogenic assay
Lungs were mechanically disrupted prior to digestion in col-
lagenase IV cocktail (Sigma-Aldrich) at 4 °C for 75 min. 
Each sample was subsequently passed through a 70-μm 
nylon cell strainer before resuspension in 10 ml of 6-TG 
media (60 mM 6-thioguanine (Sigma-Aldrich)) in 1 M 
sodium hydroxide solution diluted to 60 μm 6-thioguanine 
in 10% IMDM (IMDM supplemented with 10% FCS, 2 mM 
L-glutamine, 1 mM sodium pyruvate, 50 μg/ml penicillin 
and streptomycin). Lung suspensions were plated onto 9-cm 
tissue culture plate (Greiner) and incubated for 14 days at 
37 °C, 5%  CO2. After 14 days in culture, media were dis-
carded, and the plates were fixed with 5 ml of methanol for 
5 min. Plates were washed with sterile water and stained 
with 0.03% methylene blue dye (Sigma-Aldrich) for 5 min 
prior to washing twice with sterile water. Plates were left to 
dry, and the resulting blue colonies were counted, with each 
blue colony representing one metastatic cell [14].
In Vivo Treg depletion
DTx (native antigen) was injected intraperitoneally (i.p) at 
a concentration of 5–15 μg/kg every other day. For assess-
ing the effects of Treg depletion on the primary tumour, 
DTx was injected i.p from the day the primary tumour was 
palpable (day 5). For assessing the effects of Treg depletion 
on metastasis, mice were injected with DTx twice before 
surgery on day 0 (day 4 and day 2) or every two days after 
surgery until mice were killed. Control mice were either 
DEREG littermate controls injected with DTx as above or 
Treg-replete mice were injected i.p. with PBS at the stated 
time points.
Lung immunohistochemistry
Lungs were perfused with 5 ml of PBS and fixed in 10% 
neutral-buffered formalin in saline. Lungs were embedded 
into paraffin, and 5-μm sections were cut. To determine met-
astatic burden lung sections were stained with haematoxylin 
and eosin and then scanned using a Zeiss Axio Scan.Z1 to 
visualise the entire lung. To enumerate  CD3+ T cell infiltra-
tion into the metastatic nodules, lungs were stained with 
anti-CD3 antibodies (Dako) prior to detection with DAB 
chromogen and counterstaining with haematoxylin. Slides 
were scanned and  CD3+ T cells enumerated per metastatic 
nodule using Zen software (Zeiss).
Statistics
Statistical analysis was performed using Excel or GraphPad 
Prism 8. Unless stated otherwise in the figure legends, data 
are displayed as the mean ± SEM. Statistical significance is 
denoted as follows: *p < 0.05; **p < 0.01; ***p < 0.001.
Results and discussion
Treg depletion can promote control of metastatic 
disease
The potential of immunotherapy to cure metastatic disease is 
demonstrated by the success of treating certain cancers, most 
notably metastatic melanoma, but it remains the case that the 
vast majority of cancers still do not respond to these treat-
ments. This may reflect a lack of knowledge of the relation-
ship between the immune system and metastases. In the case 
of preclinical mouse models, novel therapies are typically 
tested on primary tumours and not on metastatic disease. 
For this reason, we examined the effect of Treg depletion 
in a clinically relevant mouse model of breast cancer. We 
hypothesised that as primary tumour control was promoted 
through Treg depletion, metastases would also be controlled 
in the same animals. In order to generate primary tumours, 
DEREG-positive mice and their negative littermates were 
injected subcutaneously with 4T1 cells with tumours becom-
ing palpable around 5 days later. At this point, injections 
with DTx were started and continued every other day until 
killing on day 21. Injections of DTx successfully depleted 
Tregs in tumours and lymph nodes (Fig. 1b and c). Tumours 
in Treg-replete mice grew uniformly, whereas many tumours 
in Treg-depleted mice began to regress after day 10, with 
some tumours demonstrating complete regression (Fig. 1d).
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To determine whether DTx treatment impinged on metas-
tases, mice were given two rounds of treatment with DTx on 
days 10 and 12 before primary tumours were resected on day 
14. A comparison of metastatic colonies revealed significantly 
fewer colonies in Treg-depleted mice (Fig. 1e and f) and signif-
icantly fewer Treg-depleted mice with any metastatic colonies 
compared to Treg-replete mice (75 versus 25%), indicating that 
Tregs do indeed promote disease progression in this model, 
since their depletion limits the number of mice with metastatic 
nodules in the lung.
Fig. 1  Depletion of Tregs can 
control growth of primary 4T1 
tumours and metastatic disease. 
a The effect of Treg-depletion 
on primary tumour growth was 
assessed as outlined. b The 
number of Tregs present within 
tumours or c tumour drain-
ing lymph nodes 7 days after 
administration of DTX (4 mice/
group). An unpaired t test was 
performed to determine signifi-
cance (P = 0.0268). d The aver-
age volumes of 4T1 tumours in 
Treg-depleted and Treg-replete 
mice are shown (6–7 mice/
group). An unpaired two-tailed 
t test was performed at each 
time point, giving the follow-
ing values: day 12 P = 0.0034, 
day 13 P =  < 0.0001, day 
16 p =  < 0.0001 and day 21 
p = 0.0002. e The impact of 
Treg-depletion on metasta-
ses following resection of 
primary tumours was assessed 
as outlined. f The number of 
metastatic colonies observed 
in the lungs of Treg-depleted 
and Treg-replete mice is shown 
(17–18 mice/group). A Mann–
Whitney test was performed 
to determine whether there 
was a statistically significant 
difference between the groups 
(p = 0.0162)
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Control of primary tumour growth predicts control 
of metastatic disease following Treg‑depletion
Since metastatic disease was not reduced in all mice after 
Treg-depletion, we next examined whether control of meta-
static disease, observed in some Treg-depleted mice, was 
linked to the size of the primary tumour at the point of Treg-
depletion or primary tumour resection. No significant asso-
ciations were observed between numbers of metastatic nod-
ules and the size of the primary tumour either at the point 
of Treg-depletion or at the point of resection indicating that 
primary tumour size does not predict control of metastasis 
after Treg-depletion (Fig. 2a and b). Primary tumour growth 
rates were measured before and after DTx treatment prior 
to tumour resection and compared to tumour growth rates 
over the same time course in Treg-replete mice (DTx-treated 
DEREG-negative littermates). As expected, in the Treg-
replete group, tumour growth rates remained unchanged 
overall at the different time points (Fig. 3a and b), whereas 
overall, tumour growth rates decreased in the Treg-depleted 
group (Fig. 3c and d). We next split the Treg-depleted group 
into those which developed metastases (Fig. 3e and f) and 
those which did not (Fig. 3g and h) and examined whether 
there was an association with individual tumour growth rates 
measured before and after Treg depletion. The data clearly 
indicate that the presence of metastases is associated with a 
failure to control the primary tumour after Treg-depletion. 
These findings are in line with a study performed by Liu and 
colleagues [19]. Whilst metastatic load was not measured 
as part of their study, they showed that the overall survival 
of tumour-bearing mice depleted of Tregs or treated with 
anti-PD1/anti-CD137 antibodies was significantly longer 
when the immunotherapy was administered prior to rather 
than after tumour resection [19]. This was associated with 
development of a  CD8+ T cell response to the  Ld-restricted 
peptide epitope, AH1 [17]. Both studies point to a critical 
requirement for the primary tumour to drive development 
of an immune response after either Treg-depletion or co-
inhibitory receptor blockade [19]. 
These findings are interesting in the context of previous 
reports indicating that primary 4T1 tumours cause general-
ised immunosuppression that is reversed following surgi-
cal resection; a finding that implies that tumour resection 
should aid induction of an anti-tumour immune response 
and not compromise it [12]. These studies however specifi-
cally compared immune responses to foreign or allogeneic 
antigens in the presence and absence of the primary tumour, 
revealing that both antibody and T cell responses generated 
against these antigens were significantly improved after 
tumour removal [12]. Our observations imply that Tregs 
play a part in tumour-driven immunosuppression but also 
show that after Treg depletion, the continued presence of 
the primary tumour is critical for enabling development of 
a successful anti-tumour T cell response. Thus, whilst the 
primary tumour does cause immunosuppression, this tumour 
is an important source of tumour antigens needed to drive 
the anti-tumour response when the immunosuppression is 
reversed. These findings are relevant since currently most 
breast cancer patients undergo surgery before other therapies 
such as chemotherapy, radiation therapy, hormone therapy 
and possibly immunotherapy. There is however a growing 
body of evidence from preclinical and clinical studies of the 
potential benefit of neoadjuvant immunotherapy [19, 20]; 
our data support this concept clearly showing that surgical 
removal of a solid primary cancer has a negative impact on 
the development of an anti-tumour response after manipu-
lating Treg.
Treg‑depletion does not limit metastatic disease 
after resection of the primary tumour
Since control of the primary tumour following depletion 
of Treg was indicative of reduced metastatic disease, we 
sought to confirm that the primary tumour was essential for 
Fig. 2  Control of metastatic disease after Treg-depletion is not linked 
to primary tumour size. The number of metastatic nodules was com-
pared to the size of the primary tumour at the point of resection a or 
b the point at which DTx treatment was initiated (17–18 mice/group)
 Cancer Immunology, Immunotherapy
1 3
induction of the protective anti-tumour immune response. 
For this purpose, tumours were resected prior to adminis-
tration of DTx in order to remove the primary tumour as a 
source of antigen for T cell priming following Treg depletion 
(Fig. 4a).
Histological analyses of tumour-bearing lungs show 
similar patterns of lymphocytic infiltrate and metastatic 
Fig. 3  Control of primary 
tumour growth predicts control 
of metastatic disease following 
Treg-depletion. Tumour growth 
rates were assessed in Treg-
replete (a) and Treg-depleted 
(c) mice and compared prior 
to and after administration of 
DTx (b, d) (17–18 mice/group). 
Within the Treg-depleted group, 
mice were split into those with 
metastatic disease (e, f) and 
those without (g, h) (8–12 mice/
group). A nonparametric one-
tailed Wilcoxon signed-rank test 
was performed on the paired 
data sets shown in individual 
graphs
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nodules of comparable size in Treg-replete and Treg-
depleted mice (Fig. 4b and c). Staining and counting of 
T cells in metastatic nodules did however reveal a sig-
nificantly higher number of tumour-infiltrating T cells 
in Treg-depleted mice (Fig. 4d and e). In spite of this, a 
comparison of metastatic colonies revealed no significant 
difference in the proportion of mice developing metastatic 
disease in Treg-depleted and Treg-replete groups (50% 
versus 64.2%), nor in the numbers of metastatic colonies 
observed in both groups (Fig. 4b).
Overall, these data show that metastatic tumours are 
not effectively controlled even after Treg-depletion reveal-
ing a fundamental difference in metastases versus primary 
tumours. This is compatible with data from a previous study 
which indicate that Treg-depletion does reduce the in situ 
formation of adenocarcinomas in a genetically engineered 
mouse model of nonsmall cell lung cancer (NSCLC) [21]. In 
Fig. 4  The presence of the primary tumour is essential for promoting 
control of metastatic disease after Treg-depletion. a DTx treatment 
was started after 4T1 tumours were resected. b Metastatic colonies 
in Treg-depleted and Treg-replete mice were compared, a Mann–
Whitney test was used to determine no significant difference was 
observed between the number of metastatic colonies in Treg-replete 
versus Treg-depleted mice (15–18 mice/group). c Haematoxylin and 
eosin staining of paraffin-embedded sections from Treg-replete ver-
sus Treg-depleted metastatic lungs. d The number of  CD3+ T cells 
(brown) per μm of metastatic nodules was calculated in the lungs of 
Treg-replete and Treg-depleted mice (9 metastatic nodules/group). e 
Representative staining of  CD3+ T cells in metastatic lung nodules 
from Treg-replete and Treg-depleted mice
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this case, the inherent immunogenicity of primary tumours 
arising in the lung may enable induction of a productive 
immune response when Treg are absent, whilst metastatic 
tumour cells, which have already undergone immune edit-
ing, fall beneath a critical immunogenicity threshold.
In the study described herein, where Treg depletion prior 
to resection of the primary tumours was shown to result in 
less metastatic disease, this is most likely due to limiting 
the establishment of metastatic nodules possibly through 
affecting dissemination, intravasation and/or survival of the 
tumour cells. The question arising from these data is why 
metastases in the lung do not induce productive immune 
responses after depletion of Treg, whilst the primary 
tumours growing in the mammary fat pad do? This cannot 
be explained by an inherent alteration in immunogenicity 
of the disseminated tumour cells, which eventually colonise 
Fig. 5  Treg-depletion does not 
result in control of 4T1 tumour 
growth after intravenous injec-
tion. a Mice injected intrave-
nously with  104 4T1 cells and 
seven days later administered 
DTx or PBS every other day 
(6 mice per group). b Meta-
static colonies were enumer-
ated 17 days later. c, d Lung 
T cells were was stained with 
AH1-dextramers (3–6 mice/
group). Statistical significance 
was determined by unpaired two 
tailed T test, *p ≤ 0.05
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the lungs compared to those in the primary tumour as even 
after delivery of a primary inoculum of 4T1 cells via the 
i.v. route, we see no difference in numbers of lung colonies 
forming in Treg-replete and Treg-depleted mice (Fig. 5b). 
This finding cannot be explained by a complete inability of 
i.v.-injected tumour cells to induce T cell responses since 
antigen-specific T cells, measured using dextramers com-
prising the AH1 peptide [17] can be seen in the lungs of 
i.v.-injected mice (Fig. 5c and d). Overall, these data imply 
that failure to control metastatic nodules in the lung is not 
due to a failure to induce T cells or a failure of T cells to 
infiltrate the lung.
We sought to confirm this finding in the case where 4T1 
cells colonise the lungs naturally as a result of dissemina-
tion from the primary tumour. For this purpose, we tested 
whether vaccination with the immunodominant 4T1 anti-
gen [17], AH1, led to improved control of metastases. Thus, 
mice were treated as shown in Fig. 4a, Treg-depleted but in 
addition, administered recombinant vaccinia virus express-
ing AH1 (Vac-AH1 [9]) or a control virus expressing influ-
enza nucleoprotein (Vac-NP [18]) at day 1 post resection. 
Vac-AH1 was used as it 1. expresses the immunodominant 
4T1  Ld-restricted peptide SPSYVYHQF (AH1), 2. elicits 
AH1-specific T cells (Supplementary Fig. 1a, b and c) and 
3. results in a significant control of 4T1 tumours in immu-
nised mice (Supplementary Fig. 1d). Moreover, this experi-
ment clearly demonstrated that  CD8+ T cells in the lungs 
of tumour-bearing mice are functional as assessed by their 
ability to produce IFN-γ (Supplementary Fig. 1e and f). 
Despite the ability of Vac-AH1 to induce T cell capable of 
both controlling the primary tumour and infiltrating the lung, 
immunisation after resection of the primary tumour had no 
impact on control of metastatic disease, despite clearly elic-
iting an AH1-specific T cell response (Fig. 6a–d).
Overall, our data indicate that once established, metas-
tases progress regardless of whether Treg are depleted and 
resist attack from the immune response generated by the pri-
mary tumour. This is the case even when antigen-specific T 
cell responses are clearly present in the lung. Whilst this may 
be due in part to immune-editing mechanisms, local barri-
ers to immune attack are likely to be multi-factorial, result-
ing from the concerted actions of many cell types including 
Fig. 6  Immunisation follow-
ing tumour resection, with 
recombinant vaccinia virus 
expressing the immunodomi-
nant peptide AH1, promotes 
tumour-specific T cells but does 
not control metastatic disease. 
a Mice were either treated with 
an irrelevant vaccine (Vac-NP) 
or a tumour antigen-specific 
vaccine (Vac-AH1) at day 1 
post tumour resection and then 
either DTx or PBS treated from 
day 2 post tumour-resection,. 
At day 14 post tumour resection 
b the metastatic colonies in 
Treg-replete and Treg-depleted 
mice were compared (3—10 
mice/group) and c splenocytes 
were stained with AH1-dex-
tramer (3—10mice/group). d 
Representative  CD8+ AH1-
dextramer+ flow cytometry 
plots from mice (shown in c) 
vaccinated with either tumour-
specific VAC-AH1, irrelevant 
VAC-NP or tumour-naïve mice
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platelets, immunosuppressive B cells and T cells, monocytes 
and macrophages [22–24]. The latter may be fundamental 
in the development of pulmonary metastases, as Qian et al. 
demonstrated that the CCL2-mediated recruitment of inflam-
matory monocytes and subsequently metastasis-associated 
macrophages (MAMs) occurs prior to infiltration of Treg. 
Furthermore, disruption of CCL2-CCR2 signalling targeted 
the MAMs and prevented metastatic seeding, with limited 
effect upon Treg [25]. CCL2 recruits inflammatory mono-
cytes to facilitate breast tumour metastasis [25]. This study 
highlights differences in the immune composition of primary 
tumours and metastases; this distinction may reflect traffick-
ing mechanisms which dictate the direction and extent to 
which immune cells access different organs.
In the case of 4T1 cells, there is evidence that myeloid-
derived suppressor cells (MDSC) create a premetastatic 
niche through production of the exosomal protein S100A8/
A9 [26], which may serve to protect subsequent tumour 
growth from immune attack, even when Treg are absent. 
There is widespread interest in the role of exosomes derived 
from malignant cells in premetastatic niche formation. 
Costa-Silva demonstrated in a model of pancreatic cancer 
that uptake of tumour-associated exosomes by the kupffer 
cells of the liver resulted in the development of a fibrotic 
environment [27]. This favoured the recruitment of MDSC 
and macrophages and the formation of a premetastatic niche 
within the liver. Subsequent studies focussing on the devel-
opment of lung premetastatic niches have shown a similar 
effect but with a preference for the recruitment of neutro-
phils [28]. As reviewed by Peinado et al. it is known that 
different tumours and their associated exosomes will form 
a premetastatic niche in organs that are conducive to their 
specific growth needs [29]. It is possible that the exosome-
induced development of metastases in the lungs of 4T1 mice 
is a process independent of Treg control.
An accumulating body of evidence also indicates that 
particular subsets of cancer-associated fibroblasts (CAF) 
are a major immunosuppressive influence in many cancers, 
including cancers of the breast ([30] and reviewed in [31]). 
By a combination of single-cell RNA sequencing and multi-
parameter phenotypic analyses, it is evident that CAF are 
highly heterogeneous, comprising cell populations of dif-
ferent origins and function. Recently, Costa and colleagues 
showed that a particular subset of CAF drives immunosup-
pression in triple-negative breast cancer [30].
Studies performed in both mice and human suggest that 
several barriers must be overcome to enable induction of 
effective anti-metastatic immune responses in the postre-
section (adjuvant) setting [32–34]. Our data suggest that 
inclusion of a cancer vaccine may still require additional 
immune-modulating regime(s), possibly based on target-
ing MDSC or distinct CAF subsets. Other possibilities 
include concomitant delivery of chemotherapy (to induce 
local immunogenic cell death) or targeted radiotherapy [35]. 
These are considerations worth exploring since delay in sur-
gical excisions may not always be possible or to the overall 
benefit of the patient.
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